1Decisions
1Patient groups
Added benefit by patient group
Decisions, newest first
Each decision lists only the patient groups coded with this disease.
Deemed proven
Erwachsene und Kinder ab 3 Monaten mit einer akuten bakteriellen Haut- und Weichgewebeinfektionen (ABSSSI)
Active substance
Dalbavancin
Appropriate comparator therapy
N/A
Data status: 2026-10-29